Sign in
Not yet taking people in United StatesPhase 3

L-citrulline given into a vein for sickle cell pain crises

Tests L-citrulline for sickle cell pain crises in young people.

Key facts

Who runs it
Asklepion Pharmaceuticals, LLC
Where
Atlanta, Baltimore, Coral Gables, Detroit, Greenville, and Washington D.C., United StatesSee the 6 sites
Trial code
Registry title
A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis
Status
Not yet recruiting
Phase
Phase 3
People taking part
120 people, planned
Started
25 Jul 2025
Expected to end
Jun 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • L-citrulline
  • Placebo
Record updated
29 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teens and young adults aged 6 to 21 with sickle cell disease who come to the emergency department with a pain crisis (vaso-occlusive crisis).

Age
6 to 21 years
Sex
All sexes can join.
Disease stage
Sickle cell disease, any genotype, in a steady state apart from a current pain crisis (VOC). Pain score above 5 on the NRS or 6 or more on the Faces Pain Scale.
Earlier treatment
Must be able to start the study treatment within 120 minutes after consent, before any later dose of IV opioid or ketamine. Cannot have used systemic steroids in the last 24 hours, or inhaled NO or blood-pressure-lowering medicines (such as nitrates, sildenafil, tadalafil, vardenafil or arginine) in the last 30 days.

Main reasons for not taking part

  • Pain lasting more than 3 days, or 9 hospital admissions in the past year
  • Another sickle cell complication such as acute chest syndrome, stroke or organ dysfunction
  • Fever above 38°C (100.4 °F) in the last 24 hours, infection, low blood pressure or unstable circulation
  • Severe anemia (hemoglobin below 6 g/dL) or serum creatinine above the age limits listed
  • Allergy to L-citrulline or dextrose, or a clinical trial of a new sickle cell therapy in the last month

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • SCD (all genotypes)
  • Children, adolescents and young adults between ages 6 to 21 years
  • In a steady disease state and not in the midst of any acute complication other than VOC due to SCD at study entry
  • Baseline NRS score >5 or Faces Pain Scale score ≥6
  • For females of childbearing potential, a negative urine pregnancy test and using an adequate method of contraception including abstinence
  • Patients or parents or legal guardian of the patient who are willing and able to sign and provide consent and assent (where appropriate for the age of the child)
  • Patients willing to begin study treatment within 120 minutes after providing informed consent/assent and soon after the first/initial dose, but before any subsequent doses of IV opioid or ketamine

Who cannot take part

  • History of 9 hospital admissions in the prior year
  • Participation in a clinical trial of a new therapy for SCD within the last 1 month
  • Systemic steroid therapy within the last 24 hours
  • Use of inhaled NO or medications that are known to cause hypotension (e.g., nitrates, sildenafil, tadalafil, vardenafil, osildenafil, or arginine) within the last 30 days
  • Presence of any other complication related to SCD such as splenic sequestration, hepatic sequestration, stroke, avascular necrosis of the hip/shoulder, acute priapism, acute renal dysfunction, acute chest syndrome and other major medical conditions or organ dysfunction
  • Presence of acute chest syndrome, sepsis, known bacterial infection, or hemodynamic instability
  • Acute stroke or clinical concern for stroke
  • History of allergic reaction to L-citrulline product or dextrose
  • Severe anemia (hemoglobin <6 g/dL)
  • Serum creatinine levels:
  • Age 6-13 years: >0.9 mg/dL
  • Age 14-17 years: >1.0 mg/dL
  • Age ≥18 years: >1.5 mg/dL
  • Patients with inability to have assent given (ages 6 to 17 years) or consent (ages 18 through 21 years); Note: Parents or legal guardians can provide consent for patients who are unable to provide assent (e.g., sleepy or preoccupied by their pain)
  • Current pain lasting >3 days
  • Hypotension requiring clinical intervention; hemodynamic instability; septic shock
  • Report of fever (>38°C) within the last 24 hours
  • Acute mental status or neurological changes
  • Unreliable venous access
  • The PI considers that the patient will be unable to comply with the study requirements
  • Patients pre-planned for admission on arrival in ED

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 21 years old?

Where in United States

  • Emory UniversityAtlanta, United StatesContact: Claudia Morris, MDNot yet recruiting
  • Johns Hopkins HospitalBaltimore, United StatesContact: Kemi Badaki-Makun, MD, PhDNot yet recruiting
  • University of MiamiCoral Gables, United StatesContact: Ofelia Alvarez, MDNot yet recruiting
  • Children's Hospital of MichiganDetroit, United StatesContact: Alexander Glaros, MDNot yet recruiting
  • East Carolina (University of North Carolina)Greenville, United StatesContact: Beng Fuh, MDNot yet recruiting
  • Children's National HospitalWashington D.C., United StatesContact: Suvankar Majumdar, MDNot yet recruiting

About the trial

What the trial wants to find out

This study is being done to learn more about a possible new treatment for pain episodes (called vaso-occlusive crises or VOCs) in children, teens, and young adults with sickle cell disease (SCD). The study will include about 120 participants between the ages of 6 and 21 who come to the emergency department (ED) with a VOC.

Read full original descriptionShow less

A VOC is a painful episode that happens with no clear cause and no signs of infection or major problems with organs like the liver or kidneys.

Before joining the study, patients and their families may be asked to learn about it and give permission (called consent or assent) while at a regular clinic visit. If that hasn't happened yet, the consent/assent process will happen at the emergency department when the patient comes in for care. If the patient meets all the study requirements, they can join the treatment part of the study.

Participants will be randomly assigned (like flipping a coin) to receive either:

L-citrulline, the study drug, or A placebo, which looks the same but has no active ingredients.

Everyone has an equal chance of getting either one. The study drug is given through an IV. It starts with one larger dose, followed by a steady infusion for up to 12 hours.

All patients in the study will still receive the usual pain treatment (called standard of care), which may include opioids. However, some patients may need fewer opioids if the study treatment helps with their pain.

If any medicines are not allowed during the study, the doctor will explain this during the consent process.

Patients can go home once:

Their pain is controlled with oral (by mouth) pain medicine, They're eating and drinking well, and They've been given a personal pain management plan to use at home.

After leaving the hospital, the study team will follow up with patients by phone about 2 days later (within a 12-hour window), again around Day 7, and again around Day 30 to check how they're doing.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison

    Participants randomized to this arm will receive a placebo intravenous (IV) treatment designed to match the appearance and administration schedule of L-citrulline. The placebo will be given as a single bolus dose followed by a continuous infusion for up to 12 hours. All participants will continue to receive standard of care pain management for sickle cell disease, consistent with the treating site's protocol and adjusted as needed based on the patient's clinical condition.

  • L-citrulline Intravenous Treatment ArmTreatment being tested

    Participants randomized to this arm will receive intravenous (IV) L-citrulline, a naturally occurring amino acid being investigated for its potential to treat vaso-occlusive crises (VOCs) in sickle cell disease. The study drug will be administered as a 50 mg/kg IV bolus, followed by a continuous infusion at 9 mg/kg/hour for up to 12 hours. The investigational product is provided as an isotonic solution in vials containing L-citrulline 50 mg/mL. Treatment will begin within 120 minutes of informed consent/assent and following the initial dose of opioid or ketamine, but prior to any subsequent doses. All participants will continue to receive standard-of-care (SoC) pain management per site protocol, which may be adjusted based on clinical response to study treatment.

    Treatment: L-citrulline

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III, Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study of Intravenous L-Citrulline in Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis in Children, Adolescents and Young Adults (6 to 21 Years)
Plain-language title
L-citrulline given into a vein for sickle cell pain crisesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06989567, who can take part
Record updated
29 May 2025